5-ASA Affects Cell Cycle Progression in Colorectal Cells by Reversibly Activating a Replication Checkpoint
Overview
Affiliations
Background & Aims: Individuals with inflammatory bowel disease are at risk of developing colorectal cancer (CRC). Epidemiologic, animal, and laboratory studies suggest that 5-amino-salicylic acid (5-ASA) protects from the development of CRC by altering cell cycle progression and by inducing apoptosis. Our previous results indicate that 5-ASA improves replication fidelity in colorectal cells, an effect that is active in reducing mutations. In this study, we hypothesized that 5-ASA restrains cell cycle progression by activating checkpoint pathways in colorectal cell lines, which would prevent tumor development and improve genomic stability.
Methods: CRC cells with different genetic backgrounds such as HT29, HCT116, HCT116(p53-/-), HCT116+chr3, and LoVo were treated with 5-ASA for 2-96 hours. Cell cycle progression, phosphorylation, and DNA binding of cell cycle checkpoint proteins were analyzed.
Results: We found that 5-ASA at concentrations between 10 and 40 mmol/L affects cell cycle progression by inducing cells to accumulate in the S phase. This effect was independent of the hMLH1, hMSH2, and p53 status because it was observed to a similar extent in all cell lines under investigation. Moreover, wash-out experiments demonstrated reversibility within 48 hours. Although p53 did not have a causative role, p53 Ser15 was strongly phosphorylated. Proteins involved in the ATM-and-Rad3-related kinase (ATR)-dependent S-phase checkpoint response (Chk1 and Rad17) were also phosphorylated but not ataxia telengectasia mutated kinase.
Conclusions: Our data demonstrate that 5-ASA causes cells to reversibly accumulate in S phase and activate an ATR-dependent checkpoint. The activation of replication checkpoint may slow down DNA replication and improve DNA replication fidelity, which increases the maintenance of genomic stability and counteracts carcinogenesis.
Ogurchenok N, Khalin K, Bryukhovetskiy I Med Int (Lond). 2024; 4(3):25.
PMID: 38628384 PMC: 11019464. DOI: 10.3892/mi.2024.149.
Partovi M, Rezayati S, Ramazani A, Ahmadi Y, Taherkhani H RSC Adv. 2023; 13(48):33566-33587.
PMID: 38020042 PMC: 10658220. DOI: 10.1039/d3ra06560j.
Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease.
Hsiao S, Yen H, Chen Y Gut Liver. 2022; 16(6):840-848.
PMID: 35670121 PMC: 9668496. DOI: 10.5009/gnl210479.
Takakura H, Horinaka M, Imai A, Aono Y, Nakao T, Miyamoto S J Clin Biochem Nutr. 2022; 70(2):93-102.
PMID: 35400827 PMC: 8921728. DOI: 10.3164/jcbn.21-74.
Promoting mechanism of serum amyloid a family expression in mouse intestinal epithelial cells.
Wakai M, Hayashi R, Ueno Y, Onishi K, Takasago T, Uchida T PLoS One. 2022; 17(3):e0264836.
PMID: 35303008 PMC: 8932556. DOI: 10.1371/journal.pone.0264836.